Patient and Clinician Views on Risk Prediction for Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, often debilitating side effect of oxaliplatin, a standard treatment for colorectal cancer. CIPN can cause pain, functional impairment, and cold hypersensitivity, frequently leading to treatment modifications that impact both quality of life and clinical outcomes. Although risk factors are known, no validated tools exist to predict an individual’s CIPN risk, limiting opportunities for proactive management. This study explored patient and clinician perspectives on CIPN risk, its effects on treatment and daily life, and the potential value of risk prediction. Semi-structured interviews were conducted with six patients with colorectal cancer treated with oxaliplatin and six clinicians (four oncologists, two nurse practitioners) from an academic hospital. Thematic analysis identified shared concerns and needs related to CIPN. Clinicians consistently described neuropathy as oxaliplatin’s most concerning side effect and reported that it often necessitated dose modifications. Patients reported sensory disturbances, functional limitations, and significant lifestyle disruption. Both groups expressed strong interest in tools to predict CIPN risk, with clinicians emphasizing the importance of clinically actionable, accurate, and workflow-integrated approaches. Findings highlight the potential of CIPN risk prediction to improve care and support treatment decisions, while demonstrating the need for strategies that balance efficacy with quality-of-life considerations.